About

Visits

Sunrise Oncology Center At Vedant Hospital

Thane West, Thane

Ghodbunder Rd, Kasarvadavali, Thane West, Mumbai, Maharashtra 400615

• Mon

  • 11am - 2pm

• Wed

  • 11am - 2pm

• Fri

  • 11am - 2pm

Available Tomorrow

or on call

Enquire Now

Consult Sunrise Oncology Center At Vedant Hospital

WhatsApp

Services

Specializations

• Oncologist
• General Medicine

Reviews

Education

1. D.M. - Medical Oncology

   D.M.(Medical Oncology) Tata Memorial Hospital, Parel, & Homi Bhabha National Institute ,Mumbai

   2019

2. M.D. - General Medicine

   GR Medical College and JAH state Government Hospital, Gwalior

   2016

3. M.B.B.S.

   Seth G S Medical College and KEM Hospital, Mumbai (Maharashtra University of Health Sciences)

   2011

Awards

1. Secured Second Position –All India Rank –in D.M./Mch

   2016

2. Secured First position in Xth standard

   2003

3. Winner of ICON Academic Grant for the Australia Asia- Pacific Clinical Oncology Research Development (ACORD) Workshop

   2018

4. Winner of Zonal Round of ISMPO organized TYSA Quiz for Medical oncology residents

   2018

5. Winner of Intra Departmental Hematology Quiz

   2018

6. Winner of Hematology Quiz at 42nd annual Mumbai Hematology Conference

   2019

7. Gold Medal at 19th national conference of FHNO 2019 for ‘Nimotuzumab cisplatin radiation versus cisplatin radiation in HPV negative oropharyngeal cancers

   2019

Experience

1. Internship

   K.E.M hospital

   2010 - 2011

2. Ad-Hoc Consultant /Specialist Registrar-Medical Oncology(Breast/ Gynaecology/Bone-Soft tissue/ Gastrointestinal Unit)

   Tata Memorial Hospital, Parel, Mumbai

   2020 - 2020

3. Specialist Registrar- and Unit Incharge Dept of Oncology –(On Deputation)

   Department of Oncology – B.K.L. Walawalkar Hospital , Chiplun Ratnagiri

   2019 - 2020

4. Senior Resident in General Medicine/ Medical Oncology

   Bharat Ratna Dr.Babasaheb Ambedkar Memorial Hospital, Central Railways, Byculla, Mumbai

   2015 - 2016

Citations

1. Molecular tumor board: Case 1-Interplay of EGFR, MET and PD-L1 in non-small cell lung carcinoma.

   2019

2. Concomitant use of corticosteroids and immune checkpoint inhibitors in patients with solid neoplasms: A real-world experience from a tertiary cancer center

   2019

3. Results of a phase II randomized controlled clinical trial comparing efficacy of Cabazitaxel versus Docetaxel as second line or above therapy in recurrent head and neck cancer.

   2017

4. Shadow study: randomized comparison of clinic with video follow-up in glioma undergoing adjuvant temozolomide therapy

   2018

5. Phase III Non-inferiority Study Evaluating Efficacy and Safety of Low Dose Gemcitabine Compared to Standard Dose Gemcitabine With Platinum in Advanced Squamous Lung Cancer.

   2019

6. A randomized phase 3 trial comparing nimotuzumab plus cisplatin chemoradiotherapy versus cisplatin chemoradiotherapy alone in locally advanced head and neck cancer

   2019

7. Phase I/II study of palliative triple metronomic chemotherapy in platinum-refractory/early-failure oral cancer

   2019

8. Nimotuzumab-cisplatin-radiation versus cisplatin-radiation in HPV negative oropharyngeal cancer

   2020

9. Concomitant use of corticosteroids and immune checkpoint inhibitors in patients with solid neoplasms: A real-world experience from a tertiary cancer center

   2019

10. Results of a phase II randomized controlled clinical trial comparing efficacy of Cabazitaxel versus Docetaxel as second line or above therapy in recurrent head and neck cancer.

    2017

11. Shadow study: randomized comparison of clinic with video follow-up in glioma undergoing adjuvant temozolomide therapy

    2018

12. Phase III Non-inferiority Study Evaluating Efficacy and Safety of Low Dose Gemcitabine Compared to Standard Dose Gemcitabine With Platinum in Advanced Squamous Lung Cancer.

    2019

13. A randomized phase 3 trial comparing nimotuzumab plus cisplatin chemoradiotherapy versus cisplatin chemoradiotherapy alone in locally advanced head and neck cancer

    2019

14. Phase I/II study of palliative triple metronomic chemotherapy in platinum-refractory/early-failure oral cancer

    2019

15. Nimotuzumab-cisplatin-radiation versus cisplatin-radiation in HPV negative oropharyngeal cancer

    2020

16. Results of a phase II randomized controlled clinical trial comparing efficacy of Cabazitaxel versus Docetaxel as second line or above therapy in recurrent head and neck cancer.

    2017

17. Shadow study: randomized comparison of clinic with video follow-up in glioma undergoing adjuvant temozolomide therapy

    2018

18. Phase III Non-inferiority Study Evaluating Efficacy and Safety of Low Dose Gemcitabine Compared to Standard Dose Gemcitabine With Platinum in Advanced Squamous Lung Cancer.

    2019

19. A randomized phase 3 trial comparing nimotuzumab plus cisplatin chemoradiotherapy versus cisplatin chemoradiotherapy alone in locally advanced head and neck cancer

    2019

20. Phase I/II study of palliative triple metronomic chemotherapy in platinum-refractory/early-failure oral cancer

    2019

21. Nimotuzumab-cisplatin-radiation versus cisplatin-radiation in HPV negative oropharyngeal cancer

    2020

22. Shadow study: randomized comparison of clinic with video follow-up in glioma undergoing adjuvant temozolomide therapy

    2018

23. Phase III Non-inferiority Study Evaluating Efficacy and Safety of Low Dose Gemcitabine Compared to Standard Dose Gemcitabine With Platinum in Advanced Squamous Lung Cancer.

    2019

24. A randomized phase 3 trial comparing nimotuzumab plus cisplatin chemoradiotherapy versus cisplatin chemoradiotherapy alone in locally advanced head and neck cancer

    2019

25. Phase I/II study of palliative triple metronomic chemotherapy in platinum-refractory/early-failure oral cancer

    2019

26. Nimotuzumab-cisplatin-radiation versus cisplatin-radiation in HPV negative oropharyngeal cancer

    2020

27. A randomized phase 3 trial comparing nimotuzumab plus cisplatin chemoradiotherapy versus cisplatin chemoradiotherapy alone in locally advanced head and neck cancer

    2019

28. Phase I/II study of palliative triple metronomic chemotherapy in platinum-refractory/early-failure oral cancer

    2019

29. Nimotuzumab-cisplatin-radiation versus cisplatin-radiation in HPV negative oropharyngeal cancer

    2020

30. Nimotuzumab-cisplatin-radiation versus cisplatin-radiation in HPV negative oropharyngeal cancer

    2020